John Kerrison, MD
Ophthalmology · Charleston, SCNPI 1952416257
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.0%), other and ownership interests — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by US Retina LLC at 58.2% of the total. Reporting peaked in 2022 at $6,071 and has fallen 86.3% since, to $834 in 2025.
Across 190 payments — averaging $63.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$7K
- Genentech USA, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$757
- Mallinckrodt Hospital Products Inc.$440
- AbbVie$431
- Apellis Pharmaceuticals, Inc.$362
- plus $2K from 19 others
Across 272 payments — averaging $3541.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kyowa Kirin, Inc.$480K
- Boehringer Ingelheim$296K
- Eyepoint US, Inc.$130K
- Ocular Therapeutix, Inc.$27K
- Genentech, Inc.$14K
- AbbVie$10K
- plus $8K from 1 others
What the payments were for
- Food & beverage$4,84740%
- Education$2102%
- Ownership interest$2,88924%
- Other$4,15734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 7 | $7,046 |
| Genentech USA, Inc. | 63 | $1,341 |
| Regeneron Healthcare Solutions, Inc. | 24 | $757 |
| Mallinckrodt Hospital Products Inc. | 14 | $440 |
| AbbVie(2 entities) | 20 | $431 |
| Apellis Pharmaceuticals, Inc. | 9 | $362 |
| Coherus Oncology, Inc. | 5 | $248 |
| Biogen | 10 | $210 |
| Novartis | 4 | $170 |
| Alcon | 2 | $154 |
| Genentech, Inc. | 1 | $150 |
| Harrow Eye, LLC | 2 | $146 |
| Eyepoint US, Inc. | 2 | $127 |
| Notal Vision, Inc. | 4 | $104 |
| Optos, Inc. | 2 | $83 |
| Mallinckrodt Enterprises LLC | 3 | $71 |
| Alimera Sciences, Inc. | 3 | $53 |
| Astellas Pharma US Inc | 2 | $43 |
| Dutch Ophthalmic, USA | 1 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Travere Therapeutics, Inc. | 6 | $19 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,102 in reported general payments places this provider in the 85th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 725 | $34,324 |
| LumiganBimatoprost | 43 | $22,225 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 89 | $13,044 |
| Latanoprost | 1,012 | $10,577 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $9,693 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $9,414 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 41 | $8,275 |
| Brimonidine Tartrate | 394 | $6,653 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 419 | $6,303 |
| Dorzolamide Hcl | 213 | $4,166 |
| ProlensaBromfenac Sodium | 12 | $4,039 |
| Ketorolac Tromethamine | 123 | $3,983 |
| Alphagan PBrimonidine Tartrate | 13 | $2,707 |
| Gentamicin Sulfate | 159 | $1,656 |
| Bromfenac Sodium | 12 | $1,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $431 | $34,34686 claims |
| AlconSimbrinza | $154 | $8,27541 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $21 | $4,03912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Charleston
- Karolinne RochaCharleston$552K
- Drew DicksonCharleston$53K
- Mona CamacciCharleston$26K
- Cole MillikenCharleston$17K
- Daniel AlfaroCharleston$15K
- Karen FernandezCharleston$13K
- Eric JablonCharleston$12K
- Marion WilsonCharleston$9K
- Michael JohnsonCharleston$9K
- Berdine BurgerCharleston$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.